These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14698079)

  • 1. Mifepristone for luteal phase contraception.
    Croxatto HB
    Contraception; 2003 Dec; 68(6):483-8. PubMed ID: 14698079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mifepristone: a potential postcoital contraceptive.
    Ho PC
    Expert Opin Pharmacother; 2001 Sep; 2(9):1383-8. PubMed ID: 11585018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of evidence and research needs on the use of mifepristone in fertility regulation: consensus from the conference.
    Contraception; 2003 Dec; 68(6):401-7. PubMed ID: 14698069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mifepristone: a potential contraceptive.
    Heikinheimo O; Archer DF
    Clin Obstet Gynecol; 1996 Jun; 39(2):461-8. PubMed ID: 8734010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of action of mifepristone when used for emergency contraception.
    Gemzell-Danielsson K; Mandl I; Marions L
    Contraception; 2003 Dec; 68(6):471-6. PubMed ID: 14698077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception.
    Gemzell-Danielsson K; Marions L
    Hum Reprod Update; 2004; 10(4):341-8. PubMed ID: 15192056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mifepristone on inhibition of ovulation and induction of luteolysis.
    Spitz IM; Croxatto HB; Lähteenmäki P; Heikinheimo O; Bardin CW
    Hum Reprod; 1994 Jun; 9 Suppl 1():69-76. PubMed ID: 7962472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiparametric study of the action of mifepristone used in emergency contraception using the Rhesus monkey as a primate model.
    Sengupta J; Dhawan L; Lalitkumar PG; Ghosh D
    Contraception; 2003 Dec; 68(6):453-69. PubMed ID: 14698076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antinidatory effect of luteal phase administration of mifepristone (RU486) is associated with changes in endometrial prostaglandins during the implantation window.
    Nayak NR; Sengupta J; Ghosh D
    Contraception; 1998 Aug; 58(2):111-7. PubMed ID: 9773266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term low-dose mifepristone on reproductive function in women.
    Croxatto HB; Kovács L; Massai R; Resch BA; Fuentealba B; Salvatierra AM; Croxatto HD; Zalányi S; Viski S; Krenács L
    Hum Reprod; 1998 Apr; 13(4):793-8. PubMed ID: 9619526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE; Kettel LM; Yen SS
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteal phase treatment with mifepristone and misoprostol for fertility regulation.
    Xiao B; von Hertzen H; Zhao H; Piaggio G
    Contraception; 2003 Dec; 68(6):477-82. PubMed ID: 14698078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergency contraception.
    Gemzell-Danielsson K; Rabe T; Cheng L
    Gynecol Endocrinol; 2013 Mar; 29 Suppl 1():1-14. PubMed ID: 23437846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ; Kettel LM; Rivier J; Burger HG; Baulieu E; Yen SS
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of progesterone antagonists and progesterone receptor modulators in contraception.
    Spitz IM; Van Look PF; Coelingh Bennink HJ
    Steroids; 2000; 65(10-11):817-23. PubMed ID: 11108893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-implantation activity of luteal phase mifepristone administration is not mimicked by prostaglandin synthesis inhibitor or prostaglandin analogue in the rhesus monkey.
    Nayak NR; Ghosh D; Lasley BL; Sengupta J
    Contraception; 1997 Feb; 55(2):103-14. PubMed ID: 9071520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placental protein 14 in endometrium during menstrual cycle and effect of early luteal phase mifepristone administration on its expression in implantation stage endometrium in the rhesus monkey.
    Lalitkumar PG; Sengupta J; Karande AA; Ghosh D
    Hum Reprod; 1998 Dec; 13(12):3478-86. PubMed ID: 9886536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.
    Gemzell-Danielsson K; Swahn ML; Svalander P; Bygdeman M
    Hum Reprod; 1993 Jun; 8(6):870-3. PubMed ID: 8345076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.